Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection

T Sakuma, T Suenaga, I Yoshida, M Azuma, T Sakuma, T Suenaga, I Yoshida, M Azuma

Abstract

The mechanism of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection was investigated by determining the effect of splenectomy, antithymocyte serum, and antimacrophage serum on resistance. It was greatly reduced by these treatments, not only in normal mice, but also in mice treated with live or heat-inactivated BCG. Production of circulating interferon by ectromelia virus and Newcastle disease virus was augmented in BCG-treated mice and was markedly depressed by splenectomy and antithymocyte and antimacrophage serum treatments in both BCG-treated and normal mice. Carbon clearance activity was activated in BCG-treated mice, but splenectomy did not influence phagocytic activity. These results suggest that augmented interferon production in the spleens of BCG-treated mice plays a major role in enhanced resistance. Other possible mechanisms are discussed.

References

    1. Curr Top Microbiol Immunol. 1981;92:83-106
    1. J Exp Med. 1976 Nov 2;144(5):1316-23
    1. J Immunol. 1970 May;104(5):1155-9
    1. Adv Exp Med Biol. 1982;155:785-97
    1. Proc Soc Exp Biol Med. 1968 Jan;127(1):207-12
    1. J Exp Med. 1976 Nov 2;144(5):1305-15
    1. Infect Immun. 1972 Oct;6(4):465-8
    1. Proc Soc Exp Biol Med. 1966 Aug-Sep;122(4):1008-11
    1. Nature. 1967 Dec 23;216(5121):1242-4
    1. Lancet. 1968 Jul 6;2(7558):37-40
    1. J Immunol. 1971 Jul;107(1):236-43
    1. J Exp Med. 1968 Jul 1;128(1):121-32
    1. Proc Natl Acad Sci U S A. 1977 May;74(5):2135-9
    1. J Immunol. 1970 May;104(5):1160-5
    1. Infect Immun. 1978 Dec;22(3):740-5
    1. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3413-6
    1. Proc Natl Acad Sci U S A. 1960 Aug;46(8):1065-75
    1. Infect Immun. 1978 Jan;19(1):225-30
    1. J Immunol. 1980 Mar;124(3):1277-83
    1. Br J Exp Pathol. 1966 Apr;47(2):168-76
    1. Adv Immunol. 1973;16:123-84
    1. J Immunol. 1977 Jan;118(1):256-63
    1. Lancet. 1969 Oct 4;2(7623):723-4
    1. Infect Immun. 1974 Dec;10(6):1383-90
    1. J Immunol. 1976 Dec;117(6):2067-72
    1. Ann Immunol (Paris). 1976 Mar-Apr;127(2):173-86
    1. J Immunol. 1978 May;120(5):1616-9
    1. Jpn J Microbiol. 1972 Nov;16(6):469-74
    1. Antimicrob Agents Chemother. 1978 Apr;13(4):566-9
    1. Infect Immun. 1978 Apr;20(1):312-4
    1. Proc Soc Exp Biol Med. 1970 Jul;134(3):865-9
    1. Jpn J Microbiol. 1975 Jun;19(3):228-31
    1. Infect Immun. 1977 Mar;15(3):686-91
    1. Infect Immun. 1975 Mar;11(3):505-11
    1. Arch Intern Med. 1970 Jul;126(1):125-34
    1. Nature. 1960 Aug 20;187:703-4
    1. Ann Microbiol (Paris). 1977 Nov-Dec;128B(4):517-30

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren